



PRESS RELEASE

ASLAN PHARMACEUTICALS TO PARTICIPATE IN FIRESIDE CHAT AT BTIG VIRTUAL BIOTECHNOLOGY CONFERENCE

Singapore, August 4, 2021 – ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 09:00am ET. The conference will be held from August 9 to August 10, 2021.

Ends

Media and IR contacts

Emma Thompson

Spurwing Communications

Tel: +65 6206 7350

Email: ASLAN@spurwingcomms.com

Ashley R. Robinson

LifeSci Advisors, LLC

Tel: +1 (617) 430-7577

Email: arr@lifesciadvisors.com

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. ASLAN has a team in the Bay Area and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on [LinkedIn](#).